Clinical Trial Update: Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant [Phase 2]

View source ↗

Summary

Phase 2 trial assessing oral azacitidine (CC-486) with fulvestrant in breast cancer was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• CC-486 (azacitidine)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Celgene | Conditions: Breast Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2018-12-14